Zomedica Other Stockholder Equity vs Property Plant And Equipment Net Analysis
| ZOM Stock | USD 0.12 0 2.50% |
Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Other Stockholder Equity and its Property Plant And Equipment Net accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Other Stockholder Equity vs Property Plant And Equipment Net
Other Stockholder Equity vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Other Stockholder Equity account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Zomedica Pharmaceuticals' Other Stockholder Equity and Property Plant And Equipment Net is 0.85. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Other Stockholder Equity and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Other Stockholder Equity i.e., Zomedica Pharmaceuticals' Other Stockholder Equity and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.85 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Other Stockholder Equity
Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 13th of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.30, while Issuance Of Capital Stock is likely to drop 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 4.0M | 6.3M | 6.6M | Interest Income | 321.1K | 2.5M | 5.6M | 5.9M |
Zomedica Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Zomedica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zomedica Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
| Other Current Liab | 1.0 | 1.2M | 45.1K | (1.0M) | (1.7M) | (1.6M) | |
| Total Current Liabilities | 2.1M | 2.0M | 4.3M | 7.8M | 9.0M | 9.5M | |
| Total Stockholder Equity | 2.1M | 51.1M | 270.9M | 267.4M | 240.0M | 252.0M | |
| Net Debt | (510.6K) | (60.1M) | (193.6M) | (25.7M) | (10.2M) | (10.7M) | |
| Retained Earnings | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (170.9M) | (162.4M) | |
| Cash | 510.6K | 62.0M | 195.0M | 27.4M | 13.0M | 12.3M | |
| Non Current Assets Total | 2.4M | 3.3M | 80.0M | 156.1M | 153.3M | 161.0M | |
| Non Currrent Assets Other | (2.4M) | 1M | 659.1K | 453K | 1.1M | 1.1M | |
| Cash And Short Term Investments | 510.6K | 62.0M | 195.0M | 115.1M | 90.5M | 95.0M | |
| Liabilities And Stockholders Equity | 4.2M | 66.1M | 280.4M | 279.6M | 253.2M | 265.9M | |
| Other Stockholder Equity | 3.6M | 2.8M | 9.3M | 23.7M | 29.9M | 31.4M | |
| Total Liab | 2.1M | 15.1M | 9.5M | 12.2M | 13.2M | 13.8M | |
| Total Current Assets | 1.8M | 62.9M | 200.4M | 123.5M | 99.9M | 104.9M | |
| Net Receivables | 67.6K | 146.2K | 765.5K | 1.9M | 2.2M | 2.3M | |
| Common Stock Shares Outstanding | 106.3M | 364.4M | 956.5M | 979.9M | 979.9M | 1.0B | |
| Other Current Assets | 1.2M | 727.8K | 1.8M | 3.8M | 2.1M | 1.4M | |
| Accumulated Other Comprehensive Income | 0.0 | 459.6K | 1.7K | (843K) | 48K | 59.2K | |
| Common Stock | 38.6M | 104.8M | 381.0M | 381.0M | 342.9M | 325.7M | |
| Net Tangible Assets | (10.4M) | 50.7M | 194.1M | 161.6M | 185.9M | 195.1M | |
| Property Plant And Equipment Net | 1.8M | 1.9M | 2.5M | 9.2M | 25.3M | 26.6M | |
| Accounts Payable | 2.1M | 1.2M | 3.2M | 6.7M | 7.7M | 8.1M | |
| Common Stock Total Equity | 38.6M | 459.6 | 381.0M | 381.0M | 438.1M | 460.0M | |
| Retained Earnings Total Equity | (52.1M) | (69.0M) | (119.4M) | (136.4M) | (122.8M) | (116.6M) | |
| Short Term Investments | 570.0K | 1.3M | 1.0M | 87.7M | 77.5M | 81.4M | |
| Property Plant And Equipment Gross | 2.4M | 583.01 | 3.4M | 10.4M | 27.3M | 28.7M | |
| Intangible Assets | 543.4K | 376.6K | 33.5M | 41.8M | 55.4M | 58.1M | |
| Property Plant Equipment | 1.8M | 583.0K | 2.5M | 6.8M | 7.8M | 8.2M | |
| Cash And Equivalents | 510.6K | 62.0M | 195.0M | 27.4M | 31.5M | 46.1M | |
| Capital Surpluse | 3.6M | 14.8M | 9.3M | 23.7M | 27.2M | 28.6M | |
| Net Invested Capital | (9.9M) | 51.6M | 270.9M | 267.4M | 240.0M | 130.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.